McKesson Corporation MCK

McKesson lifted its full-year adjusted EPS guidance after mixed quarterly estimates, though the stock slid 1.2% on the day. The shares have been choppy recently, down about 4% over 30 days despite a 90-day 13.9% gain and strong year-to-date performance; long-term investors have benefited with a one-year TSR around 18.5% and five-year gains. The company emphasizes a specialty-led footprint, especially oncology-focused services through US Oncology Network, PRISM, and Precision Medicine Group, as a central driver. The narrative suggests McKesson may be undervalued (about 11% below a fair value of $980.73 versus $869.36 close), but risks include drug pricing pressure, cyber-related costs, and potential churn. Investors are urged to consider both upside from oncology platforms and downside risks while watching valuation and peer comparisons like Cardinal Health. Raised guidance signals potential for earnings growth, but pricing pressure and cyber-security risks keep upside limited in the near term.

McKesson (MCK) closed at $880.50, down 1.2% on a day when the S&P 500 fell 0.76%, the Dow 0.68% and the Nasdaq 1.13% lower. Over the past month, MCK dropped 1.53 as the Medical sector slid 3.03% while the S&P 500 advanced 1.26%. Ahead of its upcoming earnings release, McKesson is projected to report $10.72 per share, up 8.72% year over year, on revenue of $110.14 billion, up 6.78%. For the full year, consensus calls for $44.64 per share and $429.09 billion in revenue, representing ~+14.14% and +6.36% growth, respectively. Analysts' estimates have recently shifted, and McKesson carries a Zacks Rank of #3 (Hold). Valuation shows a forward P/E of 19.96 (industry 17.01) and a PEG of 1.77 (industry ~1.95); the Medical-Dental Supplies industry ranks 104th of 250. Upcoming earnings and revised estimates could affect near-term sentiment but are unlikely to alter McKesson's long-term trajectory.

McKesson (MCK) has been highly searched on Zacks, but shares fell 1.5% last month while the S&P 500 rose 1.3% and the Medical-Dental Supplies group dropped 1.7%. Earnings revisions drive the bull case: higher forward estimates lift fair value and can support upside. For the current quarter, McKesson is expected to earn $10.72 per share, up 8.7% year over year, with the consensus up 1.4% in the last 30 days. The current fiscal year is seen at $44.64 per share (+14.1%), and next year at $49.83 (+11.6%). Revenue is projected at $110.14 billion for the quarter, $429.09 billion for this year, and $459.25 billion next year—growth of about 6–7% annually. The company has beaten EPS estimates in four straight quarters and topped revenue estimates twice. Valuation shows a Value Score of B, indicating a discount to peers. Zacks Rank #3 suggests a near-term move in line with the market. Earnings revisions suggest some upside potential but the Hold stance and mixed recent performance limit near-term impact.

McKesson reported higher EPS alongside expanded oncology initiatives that could reshape its investment narrative. EPS increase and oncology expansion mark major strategic moves likely to shift company trajectory and investor views.

McKesson raised its outlook and announced a precision medicine deal to expand oncology growth. Outlook raise plus oncology-focused acquisition signals material strategic growth and investor-positive trajectory shift.

McKesson plans a $2.25 billion precision medicine acquisition to fuel oncology expansion. The $2.25 billion precision medicine deal represents a major strategic move that could significantly boost oncology revenue and reposition McKesson in high-growth healthcare segments.

McKesson acquires a precision medicine company for $2.25 billion to expand its oncology operations. The $2.25 billion oncology-focused acquisition marks a major strategic expansion with potential to shift competitive positioning.

McKesson (MCK) shares rose 5.7% after its latest earnings report on stronger financial results, operational metrics and positive market reaction to guidance. Post-earnings stock movement reflects moderate short-term effects on sentiment and valuation without indicating major strategic shifts.

McKesson confirms data theft in cyberattack involving third-party apps. Data theft from cyberattack may trigger regulatory costs and short-term market pressure on McKesson.

McKesson Corporation acquires a precision medicine company to expand healthcare operations and accelerate growth in targeted medical services. Precision medicine acquisition marks major strategic expansion with potential to reshape McKesson's long-term healthcare positioning and performance.

McKesson Corporation expands into oncology and clinical research to capture growth in specialized healthcare services and strengthen its distribution and technology offerings. Strategic expansion into oncology and clinical research constitutes a major move that can materially shift McKesson's competitive position and long-term performance.

McKesson Corporation announced plans to acquire Precision Medicine Group to strengthen its services portfolio. Acquisition constitutes a major strategic move that could significantly alter McKesson's trajectory and investor sentiment.

McKesson to acquire Precision Medicine Group for $2.25 billion. $2.25bn acquisition marks major strategic expansion into precision medicine.

McKesson to acquire Precision Medicine Group for $2.25 billion. The $2.25 billion acquisition marks a major strategic expansion into precision medicine.

McKesson Corporation will acquire Precision Medicine Group for $2.25 billion. The 2.25 billion dollar acquisition of Precision Medicine Group significantly expands McKesson's oncology and precision medicine operations.

McKesson to acquire Precision Medicine for $2.25 billion. The $2.25 billion acquisition of Precision Medicine marks a major strategic expansion into precision medicine.

McKesson acquires Precision Medicine to expand clinical research and commercialization capabilities. Acquisition targets expansion in clinical research and commercialization for McKesson.

McKesson signs agreement to acquire Precision Medicine Group, LLC. Acquisition marks major strategic expansion into precision medicine and oncology services.

McKesson raised FY27 guidance on accelerating oncology and GLP-1 growth. Raising FY27 guidance on oncology and GLP-1 growth signals stronger future revenue trajectory.

McKesson Corporation plans to spin off its SOLV health information systems business to drive growth. Spinoff of SOLV unit constitutes major strategic restructuring with potential to significantly alter McKesson's trajectory.

McKesson Q1 earnings call highlighted financial results, operational updates and forward guidance for the company. Q1 earnings results and guidance directly shape near-term valuation and trading activity for MCK.

McKesson posted higher sales but lower EPS and issued new guidance that alters its investment outlook. Earnings results and revised guidance can materially shift investor views on McKesson's near-term trajectory.

McKesson (MCK) stock rose after Q1 earnings beat expectations due to specialty growth and the company raised guidance. Q1 earnings beat on specialty growth plus raised guidance signals stronger revenue trajectory and lifts investor outlook.

McKesson raised full-year guidance after its Q1 earnings call, with the increase driven by pharmaceutical segment performance. Guidance raise from core pharma operations signals stronger projected earnings and shifts investor expectations for McKesson.

McKesson reported robust Q1 2027 revenue growth and raised its outlook amid strong operational performance. Robust revenue growth and raised guidance signal major positive shifts in financial trajectory and investor sentiment.

McKesson reported fiscal 2027 first quarter results and raised full-year adjusted EPS guidance. Raising full-year adjusted EPS guidance signals stronger profitability outlook likely to lift investor sentiment and share price.

McKesson beats Q3 earnings on segment growth and raises EPS outlook, driving stock gains. Q3 earnings beat and raised EPS guidance signal stronger performance and boost investor sentiment.

McKesson reported Q1 earnings with key metrics compared against analyst estimates. Quarterly earnings metrics versus estimates can shift near-term investor sentiment on performance.

McKesson’s Q2 CY2026 sales exceeded estimates. Q2 sales beat signals stronger revenue that may lift near-term stock performance.

McKesson Q2 earnings met estimates as sales exceeded targets; company raised 2026 outlook and stock rose. Q2 earnings beat with raised 2026 guidance and stock gain signal moderately positive but routine effects on McKesson trajectory.